Why the study?
Studying mechanisms and optimizing treatment of SQTS-related atrial arrhythmias has been limited by the lack of relevant human atrial tissue models.
Patient-specific hiPSC-based atrial models of SQTS successfully recapitulate the disease phenotype and demonstrate that quinidine and vernakalant, but not sotalol, can reverse arrhythmia irregularities.
Background Among the monogenic inherited causes of atrial fibrillation is the short QT syndrome (SQTS), a rare channelopathy causing atrial and ventricular arrhythmias. One of the limitations in studying the mechanisms and optimizing treatment of SQTS-related atrial arrhythmias has been the lack of relevant human atrial tissues models. Objective To generate a unique model to study SQTS-related atrial arrhythmias by combining the use of patient-specific human induced pluripotent stem cells (hiPSCs), atrial-specific differentiation schemes, two-dimensional tissue modeling, optical mapping, and drug testing. Methods and results SQTS (N588K KCNH2 mutation), isogenic-control, and healthy-control hiPSCs were coaxed to differentiate into atrial cardiomyocytes using a retinoic-acid based differentiation protocol. The atrial identity of the cells was confirmed by a distinctive pattern of MLC2v downregulation, connexin 40 upregulation, shorter and triangular-shaped action potentials (APs), and expression of the atrial-specific acetylcholine-sensitive potassium current. In comparison to the healthy- and isogenic control cells, the SQTS-hiPSC atrial cardiomyocytes displayed abbreviated APs and refractory periods along with an augmented rapidly activating delayed-rectifier potassium current (I Kr ). Optical mapping of a hiPSC-based atrial tissue model of the SQTS displayed shortened APD and altered biophysical properties of spiral waves induced in this model, manifested by accelerated spiral-wave frequency and increased rotor curvature. Both AP shortening and arrhythmia irregularities were reversed by quinidine and vernakalant treatment, but not by sotalol. Conclusions Patient-specific hiPSC-based atrial cellular and tissue models of the SQTS were established, which provide examples on how this type of modeling can shed light on the pathogenesis and pharmacological treatment of inherited atrial arrhythmias.
No takes yet. Share an insight, caveat, or question.
Shiti et al. (2023) studied Short QT syndrome (SQTS). hiPSC-based atrial tissue model of SQTS and drug testing (quinidine, vernakalant, sotalol) vs. Isogenic-control and healthy-control hiPSCs was evaluated on Action potential duration, refractory periods, and spiral wave properties.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: